Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Skin cancer, neuroendocrine carcinoma (Merkel cell)
Stage/Subtype:  stage III neuroendocrine carcinoma of the skin
Trial Type:  Treatment
Results 1-11 of 11 for your search:
Start Over
A Study to Investigate the Safety and Efficacy of Nivolumab Monotherapy and Nivolumab Combination Therapy in Virus-associated Tumors
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CA209-358, NCI-2015-01356, 2015-000230-29, NCT02488759
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: Any age
Trial IDs: SCRX001-006, NCI-2016-01071, NCT02709889
PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: PEN-221-001, NCI-2017-00043, NCT02936323
Avelumab in Subjects With Merkel Cell Carcinoma (JAVELIN Merkel 200)
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 100070-003, NCI-2014-01995, 2014-000445-79, NCT02155647
Pembrolizumab in Treating Patients with Advanced Merkel Cell Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CITN-09, NCI-2014-00848, MK-3475, NCT02267603
QUILT-3.009: Study of aNK (Activated NK-92, Formerly Neukoplast) Infusions in Patients With Unresectable Stage III (IIIB) or Distant Metastatic (IV) Merkel Cell Carcinoma (MCC)
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: QUILT-3.009, NCI-2015-01343, MCC-001, NCT02465957
Ramucirumab and Somatostatin Analog Therapy in Treating Patients with Locally Advanced or Metastatic Carcinoid Tumor That Cannot Be Removed by Surgery
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 16-072, NCI-2016-00941, NCT02795858
Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: S1609, NCI-2016-01041, NCT02834013
RRx-001 in Small, Non-small Cell Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: RRx001-211-01, NCI-2016-01889, NCT02489903
Talimogene Laherparepvec and Nivolumab in Treating Patients with Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
Status: Not yet active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 10057, NCI-2016-01804, NCT02978625
Veliparib, Capecitabine, and Temozolomide in Treating Patients with Advanced, Metastatic, and Recurrent Neuroendocrine Tumor That Cannot Be Removed by Surgery
Status: Not yet active
Phase: Phase I
Type: Treatment
Age: 19 and over
Trial IDs: VICC GI 14134, NCI-2016-01044, NCT02831179
Start Over